Emcure Pharmaceuticals Posts Strong Q3 FY26 Performance; profit Surges 48%
Emcure Pharmaceuticals Ltd. announced robust financial results for the third quarter of the 2025-26 fiscal year, marking significant growth across both domestic and international businesses. The company reported a notable rise in profitability and topline performance, underpinned by diversified portfolio strength and strategic initiatives.









